Surgical Site Infection Is Associated with Tumor Recurrence in Patients with Extrahepatic Biliary Malignancies
- PMID: 28913712
- PMCID: PMC5905431
- DOI: 10.1007/s11605-017-3571-2
Surgical Site Infection Is Associated with Tumor Recurrence in Patients with Extrahepatic Biliary Malignancies
Abstract
Background: Surgical site infections (SSI) are one of the most common complications after hepato-pancreato-biliary surgery. Infectious complications may lead to an associated immune-modulatory effect that inhibits the body's response to cancer surveillance. We sought to define the impact of SSI on long-term prognosis of patients undergoing surgical resection of extrahepatic biliary malignancies (EHBM).
Methods: Patients undergoing surgery for EHBM between 2000 and 2014 were identified using a large, multi-center, national cohort dataset. Recurrence free survival (RFS) was calculated and a multivariable Cox proportional hazards model was utilized to identify potential risk factors for RFS including SSI.
Results: Seven hundred twenty-eight patients included in the analytic cohort; 236 (32.4%) patients had perihilar cholangiocarcinoma, 241 (33.1%) gallbladder cancer, and 251 (34.5%) distal cholangiocarcinoma. A major resection, liver resection, was performed in 205 (28.3%) patients, while 110 (15.2%) patients had a pancreaticoduodenectomy. The overall incidence of morbidity was 55.8%; among the 397 patients who experienced a complication, 161 patients specifically had an SSI. The SSI occurred as an infection of the surgical site (n = 70, 9.6%) or formation of an abscess in the operative bed (n = 91, 12.5%). SSI was associated with long-term survival as patients who experienced an SSI had a median RFS of 19.5 months compared with 30.5 months for those patients who did not have an SSI (HR 1.40, 95% CI 1.08-1.80; p = 0.01). Among 279 patients who had EHBM that had no associated lymph node metastases, well-to-moderate tumor differentiation, as well as an R0 resection margin, SSI remained associated with worse RFS (HR 1.84, 95% CI 1.03-3.29; p = 0.038), as well as overall survival (HR 1.87, 95% CI 1.18-2.97; p = 0.008).
Conclusion: SSI was a relatively common occurrence following surgery for EHBM as 1 in 10 patients experienced an SSI. In addition to standard tumor-specific factors, the occurrence of postoperative SSI was adversely associated with long-term survival.
Keywords: Cholangiocarcinoma; Gallbladder cancer; Recurrence free survival; Surgical site infection.
Conflict of interest statement
Figures
Similar articles
-
Different biliary tract cancers, same operation: Importance of cancer origin in patients with hilar-invading tumors.Scand J Surg. 2025 Mar;114(1):35-43. doi: 10.1177/14574969241282480. Epub 2024 Oct 8. Scand J Surg. 2025. PMID: 39380179
-
Failure to administer multimodality therapy leads to sub-optimal outcomes for patients with node-positive biliary tract cancers in the United States.Surg Oncol. 2020 Sep;34:298-303. doi: 10.1016/j.suronc.2020.06.004. Epub 2020 Jun 30. Surg Oncol. 2020. PMID: 32891346
-
Elevated CA 19-9 portends poor prognosis in patients undergoing resection of biliary malignancies.HPB (Oxford). 2010 Mar;12(2):134-8. doi: 10.1111/j.1477-2574.2009.00149.x. HPB (Oxford). 2010. PMID: 20495658 Free PMC article.
-
Outcomes in biliary malignancy.J Surg Oncol. 2014 Oct;110(5):585-91. doi: 10.1002/jso.23762. J Surg Oncol. 2014. PMID: 25250887 Review.
-
Does high-grade dysplasia/carcinoma in situ of the biliary duct margin affect the prognosis of extrahepatic cholangiocarcinoma? A meta-analysis.World J Surg Oncol. 2019 Dec 9;17(1):211. doi: 10.1186/s12957-019-1749-7. World J Surg Oncol. 2019. PMID: 31818290 Free PMC article. Review.
Cited by
-
Duration of Postoperative Fever as a Simple and Useful Prognostic Indicator in Gastric Cancer Patients.Yonago Acta Med. 2021 Aug 6;64(3):282-291. doi: 10.33160/yam.2021.08.006. eCollection 2021 Aug. Yonago Acta Med. 2021. PMID: 34429704 Free PMC article.
-
Pancreatoduodenectomy within 2 weeks after endoscopic retrograde cholangio-pancreatography increases the risk of organ/space surgical site infections: a 5-year retrospective cohort study in a high-volume centre.Gland Surg. 2021 Jun;10(6):1852-1864. doi: 10.21037/gs-20-826. Gland Surg. 2021. PMID: 34268070 Free PMC article.
-
Essential updates to the surgical treatment of biliary tract cancer.Ann Gastroenterol Surg. 2019 May 22;3(4):378-389. doi: 10.1002/ags3.12266. eCollection 2019 Jul. Ann Gastroenterol Surg. 2019. PMID: 31346577 Free PMC article.
-
Closed incision negative pressure wound therapy following pancreaticoduodenectomy for prevention of surgical site infections in high-risk patients.Can J Surg. 2023 Oct 24;66(5):E507-E512. doi: 10.1503/cjs.000723. Print 2023 Sep-Oct. Can J Surg. 2023. PMID: 37875305 Free PMC article.
-
Impact of surgical site infection (SSI) following gynaecological cancer surgery in the UK: a trainee-led multicentre audit and service evaluation.BMJ Open. 2019 Jan 24;9(1):e024853. doi: 10.1136/bmjopen-2018-024853. BMJ Open. 2019. PMID: 30679297 Free PMC article.
References
-
- Groot Koerkamp B, Fong Y. Outcomes in biliary malignancy. J Surg Oncol. 2014;110(5):585–91. - PubMed
-
- Hezel AF, Zhu AX. Systemic Therapy for Biliary Tract Cancers. The Oncologist. 2008;13(4):415–423. - PubMed
-
- Dodson RM, et al. Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg. 2013;217(4):736–750 e4. - PubMed
-
- Brito AF, et al. Cholangiocarcinoma: from molecular biology to treatment. Med Oncol. 2015;32(11):245. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources